DRUGS to KNOW: BLOCK 3 PMY 302; Questions
and Answers 100% Solved
Somatropin Drug Class CORRECT ANS-Synthetic recombinant human growth hormone
Somatropin MOA CORRECT ANS-Identical in action and abilities like endogenous secreted
GH (stimulating proliferation of bone growth plates and increased linear bone growth,
promotion of protein synthesis throughout the body)
Somatropin/Somatrem dosing CORRECT ANS-Daily dosing dependent and adjusted to
individual clinical response and IGF-1 levels
Somatropin/Somatrem pharmacokinetics CORRECT ANS-Following SC injection, 80% of the
drug will be systemically available
Somatropin/somatrem results and monitoring CORRECT ANS-Response to GH therapy is
measured every 3-6 months by height and bone age determinations
Somatropin/Somatrem Therapeutic use CORRECT ANS-Childhood Dwarfism/Growth
hormone deficiency disorders
, DRUGS to KNOW: BLOCK 3 PMY 302; Questions
and Answers 100% Solved
Somatrem Drug class CORRECT ANS-Analog of GH; synthetic recombinant human growth
hormone with Extra amino acid noted in protein makeup
Somatrem MOA CORRECT ANS-Similar to somatropin
Octreotide Acetate and Lanreotide drug class CORRECT ANS-synthetic analogs of
somatostatin
Octreotide Acetate and Lanreotide MOA CORRECT ANS-acts identical to somatostatin to
directly inhibit GH release from the anterior pituitary which effectively decreases circulating
GH and IGF-1 levels
Octreotide Acetate and Lanreotide Dosing CORRECT ANS-Long-acting depots allow for
once-a-month IM dosing due to gradual release formula (10-20 mg/4 weeks) T ½: 1-2 hours
, DRUGS to KNOW: BLOCK 3 PMY 302; Questions
and Answers 100% Solved
Octreotide Acetate and Lanreotide Therapeutic effects CORRECT ANS-suppresses GH
hypersecretions, reduces pituitary adenoma overgrowth, and normalizing levels of GH and
IGF-1
Octreotide acetate/Lanreotide/Pegvisomant Use CORRECT ANS-Acromegaly/Gigantism Tx
Pegvisomant Drug class CORRECT ANS-GH receptor antagonist
Pegvisomant MOA CORRECT ANS-Blocks actions of GH and reduces the levels of circulating
IGF-1
Pegvisomant Dosing CORRECT ANS-daily SubQ injections; increases dose until serum IGF-1
levels are maintained to be within the age-appropriate/normal range (usually within 12
months, pt. Will have normal or next to normal levels of IGF-1)
Pegvisomant drug structure CORRECT ANS-Extremely similar protein structure to GH but
acts as a receptor antagonist
, DRUGS to KNOW: BLOCK 3 PMY 302; Questions
and Answers 100% Solved
Bromocriptine/Cabergoline drug class CORRECT ANS-Dopamine Receptor Agonists
Bromocriptine/Cabergoline MOA CORRECT ANS-Decreases prolactin production and
secretions by prolactin-secreting pituitary tumors; mimics the actions of dopamine and causes
inhibition of prolactin secretion
Bromocriptine/Cabergoline Pharmacokinetics CORRECT ANS-Orally Active and effective
use in 80-85% of cases
Bromocriptine/Cabergoline Therapeutic effects CORRECT ANS-Reduces tumor size,
suppresses galactorrhea and restores normal ovulatory menstrual cycles
Bromocriptine special consideration CORRECT ANS-Longer track record of safety in use and
cheaper to produce (DOC/more commonly used)
and Answers 100% Solved
Somatropin Drug Class CORRECT ANS-Synthetic recombinant human growth hormone
Somatropin MOA CORRECT ANS-Identical in action and abilities like endogenous secreted
GH (stimulating proliferation of bone growth plates and increased linear bone growth,
promotion of protein synthesis throughout the body)
Somatropin/Somatrem dosing CORRECT ANS-Daily dosing dependent and adjusted to
individual clinical response and IGF-1 levels
Somatropin/Somatrem pharmacokinetics CORRECT ANS-Following SC injection, 80% of the
drug will be systemically available
Somatropin/somatrem results and monitoring CORRECT ANS-Response to GH therapy is
measured every 3-6 months by height and bone age determinations
Somatropin/Somatrem Therapeutic use CORRECT ANS-Childhood Dwarfism/Growth
hormone deficiency disorders
, DRUGS to KNOW: BLOCK 3 PMY 302; Questions
and Answers 100% Solved
Somatrem Drug class CORRECT ANS-Analog of GH; synthetic recombinant human growth
hormone with Extra amino acid noted in protein makeup
Somatrem MOA CORRECT ANS-Similar to somatropin
Octreotide Acetate and Lanreotide drug class CORRECT ANS-synthetic analogs of
somatostatin
Octreotide Acetate and Lanreotide MOA CORRECT ANS-acts identical to somatostatin to
directly inhibit GH release from the anterior pituitary which effectively decreases circulating
GH and IGF-1 levels
Octreotide Acetate and Lanreotide Dosing CORRECT ANS-Long-acting depots allow for
once-a-month IM dosing due to gradual release formula (10-20 mg/4 weeks) T ½: 1-2 hours
, DRUGS to KNOW: BLOCK 3 PMY 302; Questions
and Answers 100% Solved
Octreotide Acetate and Lanreotide Therapeutic effects CORRECT ANS-suppresses GH
hypersecretions, reduces pituitary adenoma overgrowth, and normalizing levels of GH and
IGF-1
Octreotide acetate/Lanreotide/Pegvisomant Use CORRECT ANS-Acromegaly/Gigantism Tx
Pegvisomant Drug class CORRECT ANS-GH receptor antagonist
Pegvisomant MOA CORRECT ANS-Blocks actions of GH and reduces the levels of circulating
IGF-1
Pegvisomant Dosing CORRECT ANS-daily SubQ injections; increases dose until serum IGF-1
levels are maintained to be within the age-appropriate/normal range (usually within 12
months, pt. Will have normal or next to normal levels of IGF-1)
Pegvisomant drug structure CORRECT ANS-Extremely similar protein structure to GH but
acts as a receptor antagonist
, DRUGS to KNOW: BLOCK 3 PMY 302; Questions
and Answers 100% Solved
Bromocriptine/Cabergoline drug class CORRECT ANS-Dopamine Receptor Agonists
Bromocriptine/Cabergoline MOA CORRECT ANS-Decreases prolactin production and
secretions by prolactin-secreting pituitary tumors; mimics the actions of dopamine and causes
inhibition of prolactin secretion
Bromocriptine/Cabergoline Pharmacokinetics CORRECT ANS-Orally Active and effective
use in 80-85% of cases
Bromocriptine/Cabergoline Therapeutic effects CORRECT ANS-Reduces tumor size,
suppresses galactorrhea and restores normal ovulatory menstrual cycles
Bromocriptine special consideration CORRECT ANS-Longer track record of safety in use and
cheaper to produce (DOC/more commonly used)
